
    
      This 12-month open-label study will provide further information regarding the long-term
      safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who
      have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001. Various
      background therapies, including acetylcholinesterase inhibitors and memantine, will be
      allowed.
    
  